WASHINGTON--(BUSINESS WIRE)--The Biologics Price Competition and Innovation Act of 2007 (BPCIA), reported out today by the Senate Health, Education, Labor and Pensions (HELP) Committee by voice vote, takes an important step toward establishing a pathway for approval of follow-on biologics, ensuring access for patients to life saving biologics, and protecting continued biomedical innovation, said the Biotechnology Industry Organization (BIO), the nation’s largest biotechnology trade association, and the Massachusetts Biotechnology Council (MBC), one of the largest state biotechnology trade associations. The organizations stated, however, that the bill also includes several provisions that cause concern for biotechnology pioneers, particularly regarding insufficient protection for patient safety and the patient-doctor relationship.
